Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients.

Daniel S PereiraRaj K MaturiKazumasa AkitaVinaya MaheshRobert B BhisitkulToshiaki NishihataEri SakotaYusuf AliEmiko NakamuraPadma BezwadaYoshikazu Nakamura

Published in: Eye (London, England) (2023)

These results demonstrate, for the first time, clinical proof of concept for aptamer based anti-FGF2 therapy of nAMD.

Keyphrases

age related macular degeneration
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
gold nanoparticles
cell therapy
smoking cessation